Journal article

Review article: prevention, diagnosis and management of COVID-19 in the IBD patient

Aysha H Al-Ani, Ralley E Prentice, Clarissa A Rentsch, Doug Johnson, Zaid Ardalan, Neel Heerasing, Mayur Garg, Sian Campbell, Joe Sasadeusz, Finlay A Macrae, Siew C Ng, David T Rubin, Britt Christensen

Alimentary Pharmacology & Therapeutics | WILEY | Published : 2020


BACKGROUND: The current COVID-19 pandemic, caused by SARS-CoV-2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immune-based therapies. However, these therapies may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complications including those from COVID-19. AIM: To summarise the scale of the COVID-19 pandemic, review unique concerns regarding IBD management and infection risk during the pandemic and assess COVID-19 management op..

View full abstract